
September/October 2004
Anders Löfgren, Ph.D., AstraZeneca, Research and Development, Södertälje, Sweden
Sabine Pfeffer - Hennig & Miriam Bellus, Novartis Pharma AG
Joseph Montgomery, FDA Center for Biologic Evaluation, Research & Review (CBER)
K. Shankland, Ph.D.1, A.J. Florence, Ph.D.2, N. Shankland, Ph.D.2, W.I.F. David1, A. Johnston, Ph.D.2, A.J. Markvardsen, Ph.D.1, G. Steele,Ph.D.3, S.D. Cosgrove,Ph.D.3
Hua Zhang, Ph.D.1 and Lawrence X. Yu, Ph.D.2, 1AstraZeneca Pharmaceuticals LP, 2Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs
Fred LaPlant, Ph.D., Analytical Research and Development Pfizer Inc.
Li Shi, Ph.D., Robert K. Evans, Ph.D., and Carl J. Burke, Ph.D., Vaccine Pharmaceutical Research, Pharmaceutical R&D, Merck Research Laboratories
Brent L. Kleintop, Ph.D., Haiying Zhang, Ph.D., and Ken L. Ray, Ph.D., Bristol-Myers Squibb Pharmaceutical Research Institute
Thorsten Fischer, ZLB Behring GmbH (formerly Aventis Behring GmbH), Department Facility Qualification
Sneha Sundaram1, Sirisha Bontha1, Kavitha Koushik2, and Uday B. Kompella1 , 1Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 2Barr Laboratories, Inc.
Richard D. Beger, Laura K. Schnackenberg, and Yvonne P. Dragan, Division of Systems Toxicology, Food and Drug Administration
Douglas Stockdale, President, Stockdale Associates, Inc.
John R. Kim and Rafik H. Bishara, Ph.D., Eli Lilly and Company
James Agalloco, Agalloco & Associates, Theodore H. Meltzer, Capitola Consultancy
Ivan Lee, Ph.D., Narayan Variankaval, Ph.D., Christopher Lindemann & Cindy Starbuck, Ph.D., Merck & Co., Chemical Engineering R&D and Analytical Research